coronavirus
cov
respons
respiratori
tract
infect
rti
affect
upper
lower
respiratori
tract
coronavirus
previous
thought
caus
benign
respiratori
infect
infect
rate
peak
winter
month
emerg
virul
member
famili
sarscov
harsh
deviat
belief
discoveri
two
new
speci
cov
infect
human
respect
confirm
high
rate
mutagenesi
genet
recombin
within
coronavirida
evolutionari
insight
gain
sequenc
comparison
differ
strain
sarscov
shown
viru
mutat
rate
nt
day
one
third
hiv
high
rate
mutat
often
lead
host
swap
gener
novel
cov
pose
signific
challeng
develop
broadspectrum
inhibitor
appropri
target
develop
broadspectrum
anticoronavir
indispens
viral
life
cycl
conserv
among
cov
main
viral
proteas
pro
play
key
role
viral
transcript
propag
progeni
virion
inhibit
enzym
gener
cystein
proteas
inhibitor
shown
inactiv
viral
replic
mous
hepat
viru
mhv
human
coronaviru
infect
cell
pro
threedomain
cystein
proteas
predominantli
occur
dimer
solut
previou
studi
conclud
dimer
requir
activ
proteas
catalyt
residu
cy
locat
cleft
first
two
domain
figur
compris
highli
conserv
activ
site
caviti
although
overal
sequenc
ident
pro
among
member
coronavir
famili
threedimension
structur
proteas
similar
figur
sequenc
conserv
pronounc
certain
region
pro
one
region
identifi
cluster
serin
residu
consist
ser
ser
adjac
activ
site
sar
pro
subsequ
alanin
mutagenesi
experi
serin
residu
perform
laboratori
indic
cluster
play
major
role
activ
proteas
also
abil
dimer
anoth
region
high
degre
conserv
consist
residu
determin
substrat
specif
subsit
activ
site
caviti
pro
unpublish
work
laboratori
although
catalyt
cy
residu
absolut
conserv
main
proteas
cov
high
similar
site
pro
among
member
three
coronavir
famili
also
well
establish
substrat
specif
studi
shown
high
conserv
residu
prefer
correspond
site
substrat
well
moreov
substrat
sequenc
deriv
ntermin
autocleavag
site
sar
pro
shown
process
equal
effici
proteas
coronavirus
compar
sarscov
therefor
design
broadspectrum
inhibitor
coronavir
main
proteas
base
substrat
mimet
appear
feasibl
strategi
drug
develop
recent
substrat
mimet
trifluoromethyl
keton
warhead
specif
target
activ
site
sar
pro
identifi
attempt
optim
lead
affin
librari
halomethyl
keton
compound
variou
substitut
toward
pro
evalu
show
result
character
five
best
compound
screen
data
present
includ
determin
bind
mechan
thermodynam
dissect
process
select
panel
proteas
result
indic
improv
affin
toward
pro
achiev
modifi
halogen
warhead
substitut
posit
reduc
compound
size
particular
interest
compound
inhibit
proteas
form
initi
revers
complex
follow
much
slower
irrevers
reaction
cy
adjac
halomethyl
result
thioether
linkag
crystallograph
structur
pro
complex
compound
indic
novel
pn
n
interact
accur
pharmacophor
model
deriv
affin
k
profil
compound
studi
work
experiment
valid
predict
model
perform
use
commerci
avail
compound
librari
indic
pharmacophor
effect
select
molecul
activ
better
lm
sar
pro
protein
purif
recombin
sar
pro
express
solubl
fraction
star
e
coli
compet
cell
invitrogen
carlsbad
ca
usa
construct
begin
residu
therefor
contain
full
ntermin
autocleavag
site
protein
cell
grown
lb
supplement
ampicillin
lg
ml
induc
mm
iptg
optic
densiti
determin
absorb
nm
greater
harvest
h
cell
resuspend
lysi
buffer
mm
potassium
phosphat
ph
mm
nacl
mm
kcl
glycerol
tritonx
mm
imidazol
cell
broken
sonic
ice
short
puls
one
second
follow
second
total
min
cell
debri
collect
centrifug
min
supernat
filter
use
lm
pore
size
filter
millipor
billerica
usa
appli
directli
nickel
affin
column
hitrap
chelat
hp
amersham
bioscienc
piscataway
nj
usa
preequilibr
bind
buffer
mm
sodium
phosphat
nacl
mm
imidazol
ph
proteas
elut
linear
gradient
mm
sodium
phosphat
mm
nacl
mm
imidazol
ph
elut
protein
buffer
exchang
mm
trishcl
ph
load
onto
qsepharos
anion
exchang
column
amersham
bioscienc
proteas
elut
gradient
mm
trishcl
nacl
ph
pool
fraction
contain
pro
exchang
storag
buffer
mm
sodium
phosphat
mm
nacl
mm
tri
phosphin
tcep
mm
edta
ph
digest
h
enterokinas
invitrogen
unit
per
lg
proteas
remov
ntermin
polyhistidin
tag
enterokinas
remov
incub
ekaway
resin
invitrogen
reaction
mixtur
pass
nickel
affin
column
remov
undigest
prote
figur
align
structur
sar
pro
pdb
id
hcov
pro
pdb
id
ibv
pro
pdb
id
tgev
pro
pdb
id
shown
ribbon
represent
colour
blue
yellow
red
green
respect
arrow
point
posit
activ
site
caviti
ca
structur
use
align
structur
align
sar
pro
structur
rmsd
valu
align
hcov
pro
ca
ibv
pro
ca
tgev
pro
ca
novel
inhibitor
sar
proteas
pro
ase
proteas
exchang
storag
buffer
concentr
mg
ml
use
immedi
experi
sampl
pure
assess
sdspage
activ
sar
proteas
pro
determin
continu
measur
kinet
assay
use
fluorogen
substrat
dabcyllysthrseralavalleuglnserglyphearglysmetglnedan
genesi
biotech
taipei
taiwan
sequenc
peptid
deriv
ntermin
autocleavag
site
proteas
flank
fluoresc
group
dabcyl
edan
increas
fluoresc
intens
upon
substrat
cleavag
monitor
cari
eclips
fluoresc
spectrophotomet
varian
use
wavelength
nm
excit
emiss
respect
experi
perform
buffer
contain
mm
sodium
phosphat
ph
mm
nacl
mm
tcep
mm
edta
enzym
activ
paramet
k
k
cat
determin
initi
rate
measur
substrat
cleavag
dimethyl
sulfoxid
dmso
reaction
initi
ad
proteas
final
concentr
nm
solut
substrat
final
concentr
lm
total
volum
microcuvett
inhibit
assay
compound
purchas
bachem
bachem
corpor
usa
compound
purchas
fluka
sigmaaldrich
corpor
st
loui
mo
usa
inhibit
assay
perform
condit
describ
kinet
assay
section
increas
concentr
substrat
lm
presenc
inhibitor
mm
data
fit
firstord
rate
exponenti
equat
p
product
fluoresc
v
initi
veloc
rate
substrat
cleavag
displac
term
account
fact
emiss
zero
start
assay
measur
k
app
appar
rate
constant
reaction
time
second
k
app
obtain
plot
function
linear
relationship
k
inactiv
rate
constant
k
equilibrium
inhibit
constant
k
micha
constant
substrat
concentr
data
continu
assay
analys
use
nonlinear
regress
analysi
softwar
origin
isotherm
titrat
calorimetri
experi
carri
use
high
precis
vpitc
titrat
calorimetr
system
microc
inc
northampton
usa
enzym
solut
calorimetr
cell
titrat
inhibitor
solut
dissolv
buffer
mm
sodium
phosphat
mm
nacl
mm
tcep
mm
edta
ph
final
dmso
concentr
heat
evolv
ligand
inject
obtain
integr
calorimetr
signal
order
compens
delay
k
inhibitor
inject
space
second
apart
heat
bind
reaction
inhibitor
enzym
obtain
differ
heat
reaction
correspond
heat
dilut
trypsin
inhibit
assay
select
compound
determin
measur
abil
inhibit
commerci
avail
bovin
pancreat
trypsin
sigma
trypsin
final
concentr
nm
compound
lm
preincub
min
prior
start
assay
reaction
initi
addit
chromogen
substrat
nabenzoyllarginin
ethyl
ester
hydrochlorid
sigma
final
concentr
lm
chang
absorb
nm
detect
use
cari
spectrophotomet
varian
experi
perform
mm
sodium
phosphat
ph
dmso
inhibit
thrombin
compound
evalu
experiment
condit
similar
trypsin
human
thrombin
sigma
preincub
compound
min
prior
start
assay
measur
final
thrombin
concentr
nm
compound
concentr
vari
lm
reaction
initi
addit
chromogen
substrat
sarproarg
pnitroanilid
dihydrochlorid
sigma
final
concentr
lm
chang
absorb
substrat
upon
cleavag
thrombin
monitor
nm
time
use
cari
spectrophotomet
varian
experi
conduct
mm
tri
ph
mm
nacl
dmso
inhibit
purifi
calpain
biovis
san
francisco
ca
usa
measur
use
fluoresc
substrat
acleuleutyrafc
reaction
initi
addit
enzym
mixtur
contain
reaction
extract
buffer
provid
biovis
presenc
dmso
substrat
calpain
inhibitor
zllyfmk
provid
manufactur
use
final
reaction
concentr
nm
standard
gaug
inhibit
compound
studi
increas
fluoresc
upon
substrat
cleavag
monitor
use
cari
eclips
fluoresc
spectrophotomet
varian
use
wavelength
nm
excit
emiss
respect
cocryst
sar
pro
compound
obtain
ad
sar
pro
mg
ml
mm
trishcl
nacl
mm
edta
mm
tcep
ph
compound
bacha
et
al
mm
dissolv
dmso
final
concentr
inhibitor
mm
mixtur
incub
room
temperatur
min
allow
protein
inhibitor
interact
centrifug
min
g
remov
aggreg
form
condit
use
crystal
wildtyp
sar
pro
use
start
condit
best
crystal
grew
hangingdrop
experi
reservoir
solut
contain
sodium
malon
ph
isopropanol
drop
made
use
reservoir
solut
protein
inhibitor
solut
crystal
appear
month
room
temperatur
data
collect
sar
pro
compound
cocryst
belong
space
group
cell
dimens
b
c
data
collect
crystal
flashfrozen
use
glycerol
cryoprotect
beam
line
nation
synchrotron
light
sourc
brookhaven
nation
laboratori
intens
data
integr
scale
reduc
structur
factor
amplitud
suit
summar
tabl
structur
cocryst
pro
compound
determin
molecular
replac
program
amor
use
wildtyp
sar
pro
pdb
id
search
model
restrain
refin
model
perform
use
refmac
manual
build
carri
use
water
molecul
place
arpwarp
stereochemistri
model
check
analys
use
procheck
molprob
coordin
structur
sar
pro
bound
compound
deposit
protein
data
bank
access
number
pharmacophor
model
gener
use
pharmacophor
applic
modul
moe
quebec
canada
binari
model
threshold
lm
select
base
distribut
k
data
compound
databas
compound
activ
k
case
lower
threshold
chosen
activ
potenc
higher
threshold
inact
low
energi
multiconform
databas
compound
librari
gener
use
forc
field
cutoff
strain
energi
kcal
mol
pharmacophor
annot
scheme
ppchall
provid
moe
use
calcul
planar
polar
charg
hydrophob
featur
includ
hydrophob
conform
librari
b
model
optim
train
set
databas
compound
activ
compound
k
lm
seven
inact
compound
k
lm
structur
activ
compound
shown
tabl
supplementari
materi
base
breakdown
ideal
model
would
select
activ
compound
posit
control
train
databas
inact
compound
neg
control
therebi
provid
ideal
enrich
factor
r
ideal
base
eqn
flexibl
align
lowest
energi
conform
activ
compound
led
identif
critic
ligand
featur
basic
level
model
arrang
annot
featur
threedimension
array
shown
figur
second
level
complex
ad
model
defin
exclus
region
compound
featur
protrud
area
exclud
model
final
select
criterion
placement
extern
shell
defin
maximum
conform
space
sampl
molecul
gradual
refin
abil
model
discrimin
activ
versu
inact
compound
improv
gaug
calcul
observ
enrich
factor
r
observ
use
eqn
train
model
pharmacophor
optim
r
observ
r
ideal
final
model
effect
calcul
use
eqn
total
activ
total
databas
virtual
screen
pharmacophor
model
use
templat
virtual
screen
commerci
avail
databas
provid
moe
contain
total
compound
screen
carri
use
moe
result
hit
compound
purchas
measur
inhibit
sar
pro
fluorogen
assay
explain
earlier
compound
test
k
lm
includ
two
fals
posit
k
lm
base
activ
fals
posit
select
model
r
observ
r
ideal
effect
calcul
use
eqn
respect
product
purchas
chemdiv
chemdiv
inc
san
diego
ca
usa
product
purchas
sigma
sigmaaldrich
corp
usa
product
purchas
chembridg
chembridg
corp
usa
product
purchas
florida
center
heterocycl
compound
univers
florida
usa
product
purchas
interchim
franc
catalyt
mechan
lead
gener
cystein
proteas
like
serin
proteas
employ
mechan
involv
format
acylenzym
intermedi
hydrolys
via
format
tetrahedr
adduct
accord
mechan
thiol
group
catalyt
cy
sar
pro
initi
nucleophil
attack
carbonyl
flank
sessil
peptid
bond
substrat
imidazol
ring
side
chain
act
gener
base
proton
later
donat
leav
group
tetrahedr
intermedi
substrat
specif
studi
sar
pro
indic
subsit
show
prefer
gln
site
substrat
larg
subsit
hand
accommod
leu
ile
phe
val
met
posit
subsit
conserv
among
coronavirus
residu
site
gener
solvent
expos
therefor
well
defin
subsit
favour
hydrophob
side
chain
fit
caviti
posit
usual
occupi
ala
nativ
substrat
base
upon
inform
previous
gener
librari
substrat
mimet
link
trifluoromethyl
keton
warhead
show
moder
affin
toward
pro
best
compound
shown
figur
glu
leu
val
character
k
lm
order
optim
effect
compon
scaffold
overal
affin
toward
pro
evalu
three
specif
aspect
scaffold
emphas
halogen
warhead
ii
compound
size
iii
substitut
posit
scaffold
monopeptid
dipeptid
tripeptid
mimet
modif
halogen
content
warhead
posit
select
screen
pro
use
vitro
kinet
assay
result
best
five
compound
screen
shown
tabl
along
gener
scaffold
use
optim
compound
monochloromethyl
keton
warhead
alter
r
site
scaffold
correspond
posit
compound
phe
naphthalen
pfluoro
phenyl
deriv
posit
respect
compound
monobromomethyl
keton
warhead
aliphat
substitut
posit
compound
dipeptid
formic
acid
methyl
ester
posit
val
r
site
correspond
posit
inhibit
result
compound
gener
reaction
scheme
use
analys
inhibit
kinet
shown
scheme
ei
indic
revers
enzym
e
inhibitor
complex
subsequ
undergo
inactiv
step
form
irrevers
e
complex
k
revers
step
measur
ratio
k
k
k
ratelimit
inactiv
step
similar
scheme
use
earlier
measur
inhibit
halomethyl
keton
cystein
proteas
possibl
mechan
inactiv
step
scheme
thought
initi
thiolat
imidazolium
ion
pair
activ
site
toward
warhead
carbonyl
lead
format
thiohemiket
complex
subsequ
undergo
alkyl
reaction
form
irrevers
product
halomethyl
posit
compound
highest
inhibitori
potenc
compound
k
nm
shown
tabl
naphthalen
substitut
posit
compound
reduc
potenc
k
nm
addit
fluorin
para
posit
phenyl
ring
chang
potenc
compound
k
nm
although
gln
tradit
present
posit
hydrophob
moieti
also
highli
toler
toler
consist
previou
studi
modif
posit
includ
lactam
ring
stereochemistri
ketoglutamin
analog
phenyl
group
b
unsatur
ester
show
stark
improv
inhibitori
potenc
compound
proteas
compound
bromomethyl
keton
warhead
aliphat
substitut
posit
k
valu
nm
may
also
bind
similar
conform
compound
monofluoromethyl
keton
warhead
k
valu
nm
alter
methyl
ester
posit
compound
carboxyl
acid
complet
render
inact
k
lm
tabl
supplementari
materi
indic
larger
footprint
occupi
dipeptid
compound
lead
alter
conform
compound
compar
monopeptid
compound
substitut
orient
fit
hydrophob
pocket
sensit
structur
chang
hydrophob
moieti
provid
addit
van
der
waal
interact
site
improv
affin
ligand
previou
report
shown
halomethylketon
compound
react
thiol
form
thioether
also
well
document
warhead
form
methyl
phosphonium
salt
reduc
agent
phosphin
phosphinomethyl
keton
compound
previous
shown
inhibit
cystein
serin
proteas
rais
possibl
compound
present
studi
may
interact
proteas
due
reaction
tri
phosphin
tcep
present
buffer
howev
loss
inhibit
observ
kinet
measur
compound
perform
absenc
tcep
result
indic
activ
speci
inhibit
proteas
halomethyl
keton
phosphinomethyl
keton
alter
halogen
substitut
warhead
also
substanti
effect
reactiv
inhibitor
substrat
analogu
chloromethyl
keton
shown
inhibit
cathepsin
b
papain
wherea
fluoromethyl
keton
shown
activ
caspas
calpain
cathepsin
b
well
furthermor
nmr
experi
indic
fluoromethyl
chloromethyl
keton
abl
activ
carbonyl
carbon
keton
facilit
format
thiohemiket
activ
site
cystein
proteas
high
rate
inactiv
k
relat
abil
warhead
accept
nucleophil
attack
thiol
side
chain
lead
eventu
alkyl
inactiv
constant
k
compound
second
almost
twice
compound
second
second
tabl
larger
moieti
compound
may
orient
warhead
conform
favour
react
thiol
side
chain
cy
inactiv
constant
dipeptid
compound
second
similar
compound
k
compound
small
measur
accur
kinet
assay
second
indic
irrevers
step
slow
sever
hour
compound
behav
revers
inhibitor
fact
activ
proteas
complet
recov
incub
lm
compound
time
k
min
case
complet
irrevers
inhibit
proteas
would
inactiv
high
inhibitor
concentr
case
revers
interact
howev
activ
recov
inhibitor
concentr
dilut
irrevers
enzym
activ
notic
incub
time
exceed
hour
high
concentr
compound
data
shown
revers
interact
bromomethyl
keton
warhead
compound
somewhat
unexpect
bromin
deriv
gener
better
leav
group
therefor
reactiv
chlorin
fluorin
deriv
reaction
nucleophil
thiol
cystein
proteas
result
studi
point
much
lower
reactiv
warhead
format
revers
complex
follow
irrevers
alkyl
also
inactiv
constant
k
compound
studi
lower
report
dipeptidyl
halomethyl
keton
human
cathepsin
b
howev
rate
inactiv
depend
orient
compound
warhead
activ
site
differ
pro
bind
energet
compound
also
determin
isotherm
titrat
calorimetri
itc
calorimetr
titrat
compound
character
larg
reaction
heat
kcal
mol
consist
format
coval
complex
expect
fast
irrevers
rate
compound
compound
hand
differ
thermodynam
signatur
consist
observ
irrevers
step
compound
extrem
slow
character
time
constant
k
larger
min
ie
within
calorimet
bind
reaction
occur
equilibrium
condit
figur
show
calorimetr
titrat
compound
pro
bind
compound
character
small
favour
bind
enthalpi
dh
kcal
mol
favour
entrop
contribut
td
kcal
mol
result
overal
gibb
energi
kcal
mol
dissoci
constant
k
determin
calorimetr
amount
nm
close
k
valu
estim
kinet
inhibit
data
select
measur
affin
compound
intend
target
versu
affin
protein
especi
belong
class
select
defin
follow
ratio
halomethyl
keton
warhead
shown
select
target
serin
cystein
proteas
trypsin
thrombin
serin
proteas
play
major
role
digest
system
bloodclot
cascad
respect
first
two
domain
pro
antiparallel
bbarrel
structur
reminisc
chymotrypsin
fold
also
observ
picornaviru
proteas
furthermor
crystal
structur
proteas
show
presenc
two
topolog
equival
sixstrand
bbarrel
similar
trypsinlik
serin
proteas
thrombin
order
investig
select
protein
shown
surfac
represent
defin
substrat
subsit
highlight
shown
red
rose
blue
depict
yellow
nonsubsit
residu
shown
grey
novel
inhibitor
sar
proteas
pro
inhibitor
abil
inhibit
serin
proteas
trypsin
thrombin
well
cystein
proteas
calpain
test
result
experi
shown
tabl
b
inhibitor
found
highli
select
toward
sar
pro
compar
three
proteas
none
inhibitor
activ
trypsin
even
though
inhibit
measur
solubl
limit
inhibitor
reach
similar
result
also
obtain
inhibit
measur
thrombin
case
k
valu
compound
within
detect
limit
valu
lm
respect
indic
compound
time
select
toward
pro
thrombin
tabl
compound
show
higher
affin
cystein
proteas
calpain
compar
trypsin
thrombin
chloromethyl
keton
compound
k
valu
calpain
lm
respect
tabl
compound
k
lm
calpain
compound
k
lm
calcul
select
compound
respect
toward
pro
compar
calpain
tabl
halomethyl
keton
compound
lower
affin
toward
calpain
despit
fact
warhead
reactiv
toward
thiol
side
chain
activ
site
cystein
proteas
case
type
warhead
affin
compound
domin
reactiv
warhead
interact
entir
compound
residu
bind
caviti
observ
indic
compound
optim
improv
potenc
specif
toward
pro
structur
wildtyp
sar
pro
bound
compound
determin
use
xray
crystallographi
crystal
condit
similar
use
wildtyp
proteas
although
length
time
requir
crystal
form
presenc
ligand
longer
free
proteas
three
month
versu
one
week
structur
determin
molecular
replac
use
sar
pro
pdb
id
search
model
data
collect
refin
statist
summar
tabl
crystal
belong
space
group
inhibitor
bind
within
substratebind
cleft
form
chymotrypsinlik
fold
enzym
figur
electron
densiti
portion
compound
observ
final
structur
thiol
cy
coval
bound
carbon
adjac
warhead
carbonyl
origin
bond
bromin
densiti
portion
compound
correspond
r
moieti
ligand
miss
figur
show
chemic
structur
compound
electron
densiti
f
c
map
absenc
electron
densiti
atom
consist
mass
spectrometri
experi
indic
compound
begin
degrad
h
solut
reflect
mass
consist
loss
tertbutyl
group
posit
data
shown
remaind
r
group
may
visibl
structur
high
flexibl
region
compound
key
residu
involv
proteinligand
interact
shown
figur
compound
form
thioether
attach
carbon
origin
bond
bromin
c
addit
backbon
amid
gli
tabl
togeth
observ
suggest
initi
bind
event
like
follow
nucleophil
attack
c
cy
carbonyl
carbon
warhead
result
format
revers
tetrahedr
complex
subsequ
follow
slow
irrevers
rearrang
thioether
bromin
observ
structur
leav
group
rearrang
optim
tool
pharmacophor
model
gener
base
activ
data
train
databas
contain
compound
k
lm
assign
activ
compound
k
lm
inact
bacha
et
al
orient
essenti
featur
make
scaffold
librari
lead
compound
viabil
model
optim
process
determin
access
abil
discrimin
true
fals
posit
order
gener
accur
model
maximum
structur
divers
compound
train
set
incorpor
set
threshold
valu
lm
pharmacophor
model
gener
base
activ
data
combin
structur
inform
compound
tabl
final
refin
pharmacophor
model
shown
figur
contain
follow
featur
nonplanar
hydrophob
featur
sphere
radiu
red
planar
donor
featur
sphere
radiu
purpl
planar
hydrophob
nonplanar
hydrophob
featur
sphere
radiu
blue
planar
acceptor
planar
donor
featur
sphere
radiu
yellow
planar
hydrophob
featur
sphere
radiu
green
model
select
activ
molecul
train
databas
provid
r
observ
valu
select
threshold
theoret
effect
model
calcul
ratio
r
observ
r
ideal
eqn
applic
model
better
visual
examin
molecul
select
basi
structur
constraint
impos
model
figur
nonplanar
hydrophob
featur
defin
region
correspond
warhead
molecul
structur
featur
defin
subsit
planar
hydrophob
nonplanar
hydrophob
featur
result
agre
kinet
data
discuss
earlier
indic
compound
highest
affin
pro
either
phenyl
planar
moieti
flexibl
aliphat
chain
tabl
b
figur
queri
use
virtual
screen
panel
featur
pharmacophor
shown
sphere
dot
configur
along
extern
shell
shown
grey
dot
configur
aplanar
hydrophob
featur
render
red
planar
hydrophob
featur
green
planar
donor
featur
purpl
planar
aplanar
hydrophob
featur
blue
planar
donor
acceptor
yellow
panel
b
queri
align
select
conform
compound
shown
conform
select
molecul
dictat
orient
sphere
repres
pharmacophor
featur
warhead
featur
specifi
aplanar
hydrophob
featur
red
residu
planar
donor
purpl
planar
aplanar
hydrophob
featur
blue
compound
backbon
planar
donor
acceptor
yellow
termin
group
defin
planar
hydrophob
featur
green
librari
screen
model
valid
pharmacophor
model
defin
valid
use
conform
databas
approxim
compound
provid
moe
pharmacophor
search
test
set
result
select
molecul
hit
hypothesi
binari
model
select
molecul
would
inhibit
pro
k
lm
lower
unselect
molecul
k
greater
threshold
base
hypothesi
r
ideal
calcul
use
eqn
common
featur
compound
hit
presenc
halomethyl
keton
group
possess
adjac
aromat
moieti
abil
select
compound
inhibit
pro
measur
k
lm
fals
posit
k
greater
threshold
result
r
observ
base
result
observ
effect
model
calcul
data
best
compound
valid
step
shown
tabl
result
provid
evid
accuraci
pharmacophor
model
compound
highest
affin
k
lm
encourag
base
fact
compound
chosen
databas
special
halomethyl
keton
use
pharmacophor
broad
threshold
initi
model
perform
well
train
randomli
chosen
test
set
databas
establish
attract
scaffold
optim
unexpect
warhead
moder
affin
product
product
tabl
also
recov
first
optim
cycl
activ
data
valid
step
use
refin
pharmacophor
reduc
threshold
limit
consequ
sensit
model
eventu
highli
special
pharmacophor
develop
would
select
high
affin
compound
pro
featur
defin
model
identif
inhibitor
target
toward
highli
conserv
main
proteas
pro
pro
coronavirus
import
step
toward
develop
new
class
antivir
paper
shown
halomethyl
keton
potent
select
inhibitor
sar
proteas
pro
inhibitor
like
compound
end
form
coval
thioether
complex
slow
fashion
h
allow
bind
reaction
control
revers
thermodynam
interact
compound
bind
favour
enthalpi
entropi
chang
sinc
compound
molecular
weight
da
potenti
much
improv
potenc
select
